What is claimed is:
1. A method of regenerating a mesenchymally-derived tissue, comprising contacting said tissue with a composition comprising an isolated adult mesenchymal stem cell, said mesenchymal stem cell comprising an exogenous nucleic acid encoding an akt gene.
2. The method of claim 1, wherein said tissue is selected from the group consisting of connective tissue, epithelial tissue, nervous tissue and muscle tissue.
3. The method of claim 1, wherein said tissue is selected from the group consisting of myocardial, brain, spinal cord, bone, cartilage, liver, muscle, lung, vascular, and adipose tissue.
4. The method of claim 2, wherein said muscle tissue comprises skeletal muscle.
5. The method of claim 2, wherein said muscle tissue comprises smooth muscle.
6. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenous nucleic acid encoding a homing molecule.
7. The method of claim 6, wherien said homing molecule is selected from the group consisting of a chemokine receptor, an interleukin receptor, an estrogen receptor, an integrin receptor
8. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenous nucleic acid encoding a hormone.
9. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenous nucleic acid encoding an angiogenic factor.
10. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenous nucleic acid encoding a bone morphogenetic protein.
11. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenogenous nucleic acid encoding an extracellular matrix protein.
12. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenous nucleic acid encoding a cytokine or growth factor.
13. A composition comprising an apoptosis-resistant primary stem cell, said stem cell comprising an exogenous akt gene, wherein apoptosis of said cell is reduced by at least 10% compared to a primary mesenchymal stem cell lacking said akt gene.
14. The composition of claim 13, wherein said stem cell is an adult bone-marrow derived mesenchymal cell.
15. The composition of claim 13, wherein said apoptosis is reduced by at least 50%.
16. The composition of claim 13, wherein said apoptosis is reduced by at least 2-fold.
17. The composition of claim 13, wherein said apoptosis is reduced by at least 5-fold.
18. The composition of claim 13, wherein said apoptosis is reduced by at least 10-fold.
19. The composition of claim 13, wherein said stem cell is non-tumor forming.
20. The composition of claim 13, wherein said stem cell further comprises a homing receptor.
21. A method of regenerating an injured myocardial tissue, said method comprising contacting said tissue with the composition comprising an isolated adult recombinant mesenchymal stem cell (rMSC), said rMSC comprising an exogenous nucleic acid operably linked to a promoter, wherein said nucleic acid expresses a therapeutically effective amount of an anti-apoptotic gene.
22. The method of claim 21 wherein said mesenchymal stem cells are administered to an individual to regenerate or repair cardiac muscle that has been damaged through disease.
23. The method of claim 22 wherein said mesenchymal stem cells are administered to an individual who has suffered myocardial infarction.
24. The method of claim 22 wherein said mesenchymal stem cells are administered directly to the heart.
25. The method of claim 22 wherein said mesenchymal stem cells are administered systemically.
26. The method of claim 25 wherein said mesenchymal stem cells are administered by injection.
27. The method of claim 22 wherein said mesenchymal stem cells are human.
28. The method of claim 27 wherein said mesenchymal stem cells are administered to an individual who has suffered myocardial infarction.
29. The method of claim 28 wherein said mesenchymal stem cells are administered directly to the heart.
30. The method of claim 28 wherein said the mesenchymal stem cells are administered systemically.
31. A method of regenerating myocardial tissue, said method comprising contacting said tissue with the composition comprising an isolated adult recombinant mesenchymal stem cell (rMSC), said rMSC comprising an exogenous nucleic acid operably linked to a promoter, wherein said nucleic acid expresses a therapeutically effective amount of a cell protective polypeptide, wherein the expression of said polypeptide is induced by a triggering agent or condition.
32. The method of claim 31, wherein the condition is hypoxia or oxidative stress.
33. The method of claim 31, wherein the agent is an antibiotic
34. The method of claim 33, wherein said antibiotic is tetracycline.
35. The method of claim 31, wherein the agent is an immunosuppressive.
36. The method of claim 35, wherein said immunosuppressive is rapamycin.
37. The method of claim 31, wherein the agent is a hormone receptor antagonist.
38. The method of claim 37, wherein said hormone receptor antagonist is mifepristone.
39. The method of claim 31, wherein the cell protective polypeptide is selected from the group consisting of an antioxidant enzyme protein, a heat shock protein, an anti-inflammatory protein, a survival protein, an anti-apoptotic protein, a coronary vessel tone protein, a pro-angiogenic protein, a contractility protein, a plaque stabilization protein, a thromboprotection protein, a blood pressure protein and a vascular cell proliferation protein.
40. The method of claim 31, wherein the subject is at risk of developing a condition characterized by aberrant cell damage.
41. The method of claim 31, wherein said aberrant cell damage is apoptotic cell death.
42. The method of claim 31, wherein said subject is at risk of developing stroke, myocardial infarction, chronic coronary ischemia, arteriosclerosis, congestive heart failure, dilated cardiomyopathy, restenosis, coronary artery disease, heart failure, arrhythmia, angina, atherosclerosis, hypertension, renal failure, kidney ischemia or myocardial hypertrophy.
43. The method of claim 21, wherein at least 20% of said injured myocardial tissue is regenerated.
44. A composition comprising an isolated mesenchymal stem cell comprising an exogenous nucleic acid encoding a tissue protective polypeptide, a oxygen sensitive regulatory element and a cell targeting element, wherein the expression of said polypeptide is regulated by said regulatory element
45. The composition of claim 44, wherein said oxygen sensitive regulatory element is a hypoxia response element.
46. The composition of claim 44, wherein said oxygen sensitive regulatory element is a oxidative stress response element.
47. The composition of claim 46, wherein said oxidative stress response element is a peroxidase promoter.
48. The composition of claim 44, wherein said cell targeting element is selected from the group consisting of -MHC, myosin light chain-2, troponin T.
49. The composition of claim 44, wherein the composition comprises vector selected from the group consisting of an adeno-associated virus vector, lentivirus vector retrovirus vector.
50. The composition of claim 44, wherein the composition comprises an adeno-associated virus vector.
51. A method of inhibiting apoptosis of engrafted cells in a mammal, said method comprising administering to said mammal a composition comprising an isolated mesenchymal stem cell comprising an exogenous nucleic acid encoding a polypeptide selected from the group consisting of: an extracellular superoxide dismutase polypeptide, a heme oxygenase polypeptide, and an Akt polypeptide, wherein said mammal is suffering from or at risk of developing a cardiac disorder.
52. The method of claim 51, wherein said cardiac disorder is selected from the group consisting of chronic coronary ischemia, arteriosclerosis, congestive heart failure, angina, atherosclerosis, and myocardial hypertrophy.
53. The method of claim 51, wherein said composition comprises an adeno-associated virus vector.
54. The method of claim 51, wherein the human heme oxygenase-1 nucleic acid is operatively linked to a promoter.
55. The method of claim 54, wherein said promoter is a human cytomegalovirus immediate early promoter.
56. The method of claim 51, wherein said human heme oxygenase-1 nucleic acid is operatively linked to a bovine growth hormone polyadenylation signal.
57. The method of claim 56, wherein said bovine growth hormone polyadenylation signal is flanked by the adeno-associated viral inverted terminal repeats.
58. The method of claim 51, wherein said composition is administered at a dose sufficient to increase survival of engrafted mesenchymal stem cell oxidative stress-induced cardiomyocyte cell death.
59. A method of increasing post-transplantation survival of engrafted cells in a mammal in a mammal, said method comprising administering to said mammal a composition comprising an isolated mesenchymal stem cell comprising an exogenous nucleic acid encoding a polypeptide selected from the group consisting of: an extracellular superoxide dismutase polypeptide, a heme oxygenase polypeptide, and an Akt polypeptide, thereby increasing survival of the engrafted cells.
60. The method of claim 59, mammal is at risk of a cardiac disorder.
61. The method of claim 59, wherein said cardiac disorder is selected from the group consisting of myocardial infarction, chronic coronary ischemia, arteriosclerosis, congestive heart failure, angina, atherosclerosis, and myocardial hypertrophy.
62. The method of claim 59, wherein said composition comprises an adeno-associated virus vector.
63. The method of claim 59, wherein the extracellular superoxide dismutase nucleic acid is operatively linked to a promoter.
64. The method of claim 63, wherein said promoter is a human cytomegalovirus immediate early promoter.
65. The method of claim 59, wherein said extracellular superoxide dismutase polypeptide nucleic acid is operatively linked to a bovine growth hormone polyadenylation signal.
66. The method of claim 65, wherein said bovine growth hormone polyadenylation signal is flanked by the adeno-associated viral inverted terminal repeats.
67. The method of claim 59, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced cardiomyocyte cell death.
68. A method of treating a cardiac disorder, comprising identifying a mammal suffering from or at risk of developing said disorder and administering to said mammal a composition comprising an isolated mesenchymal stem cell comprising an exogenous nucleic acid expressing therapeutic amounts of a polypeptide selected from the group consisting of: an extracellular superoxide dismutase polypeptide, a heme oxygenase polypeptide, and an Akt polypeptide.
69. The method of claim 68, wherein said composition comprises an adeno-associated virus vector.
70. The method of claim 69, wherein the extracellular superoxide dismutase polypeptide nucleic acid is operatively linked to a promoter.
71. The method of claim 70, wherein said promoter is a human cytomegalovirus immediate early promoter.
72. The method of claim 68, wherein said extracellular superoxide dismutase nucleic acid is operatively linked to a bovine growth hormone polyadenylation signal.
73. The method of claim 72, wherein said bovine growth hormone polyadenylation signal is flanked by the adeno-associated viral inverted terminal repeats.
74. The method of claim 68, wherein said cardiac disorder is selected from the group consisting of myocardial infarction, chronic coronary ischemia, arteriosclerosis, congestive heart failure, dilated cardiomyopathy, restenosis, coronary artery disease, heart failure, arrhythmia, angina, atherosclerosis, hypertension, renal failure, kidney ischemia or myocardial hypertrophy, and stroke.
75. A cardioprotective agent comprising a recombinant adeno-associated viral vector comprising nucleotide encoding a extracellular superoxide dismutase polypeptide operatively linked to a human cytomegalovirus immediate early promoter.
76. The cardioprotective agent of claim 75, further comprising a bovine growth hormone polyadenylation signal.
77. The cardioprotective agent of claim 76, wherein said bovine growth hormone polyadenylation signal is flanked by the adeno-associated viral inverted terminal repeats.
78. A method for reducing scar formation in infarcted heart tissue, said method comprising contacting said tissue with the composition comprising an isolated adult recombinant mesenchymal stem cell (rMSC), said rMSC comprising an exogenous nucleic acid operably linked to a promoter, wherein said nucleic acid expresses a therapeutically effective amount of an anti-apoptotic gene.
79. A composition comprising an isolated adult recombinant mesenchymal stem cell (rMSC), said rMSC comprising an exogenous nucleic acid operably linked to a promoter, wherein said nucleic acid expresses a therapeutically effective amount of an anti-apoptotic gene.
80. The composition of claim 79, wherein the anti-apoptotic gene is selected from the group consisting of an Akt gene, an extracellular superoxide dismutase (ecSOD) polypeptide and a heme oxygenase gene.
81. A method of enhancing migration of a stem cell to an injured tissue, comprising increasing the amount of a stem cell polypeptide on the surface of said stem cell, wherein said stem cell polypeptide is selected from the group consisting of CXCR4, IL-6RA, IL-6ST, CCR2, Selel, Itgalb2, Itgamb2, Itga41b 1, Itga8b 1, Itga6b 1, and Itga9b 1.
82. The method of claim 81, wherein said cell is a bone marrow-derived stem cell.
83. The method of claim 81, wherein said cell is a mesenchymal stem cell.
84. The method of claim 81, wherein said method comprises introducing into said stem cell a nucleic acid encoding said receptor.
85. A method of enhancing engraftment of a stem cell to an injured tissue, comprising increasing the amount of an injury-associated polypeptide in said injured tissue, wherein said injury-associated polyeptide is selected from the group consisting of SDF1, IL-6, CCL2, Sele, ICAM-1, VCAM-1, FN, LN, and Tnc.
86. The method of claim 85, wherein said injured tissue is cardiac tissue.
87. The method of 85, wherein said injured tissue is ischemic myocardial tissue.
88. The method of claim 85, wherein said method comprises contacting said injured tissue with a nucleic acid encoding said injury-associated polypeptide.
89. The method of claim 85, wherein said method comprises contacting said injured tissue with said injury-associated polypeptide.
90. The method of claim 85, wherein said method comprises injecting said injury-associated polypeptide or a nucleic acid encoding said polypeptide directly into the myocardium.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A testing machine comprising:
a frame;
a roadway assembly comprising:
first roller;
a second roller;
an endless belt supported by and rolling on the first roller and the second roller; and
a carriage supporting the first roller and the second roller in spaced apart relation to cause a flat portion in the endless belt, the carriage being pivotally coupled to the frame to move relative to the frame about at least one axis that is perpendicular to an axis that is parallel to an axis of rotation of the first roller, the carriage including a bearing arranged to support an inner surface of the flat portion of the endless belt;
a spindle carriage having a spindle arranged to support a tire and wheel assembly, the spindle carriage movably mounted on the frame to move the spindle toward and away from the flat portion;
a drive operably coupled to the drive roller or the spindle; and
an actuator to control pivotal movement of the roadway assembly about said at least one axis.
2. The testing machine of claim 1 and wherein the endless belt includes a second flat portion and the carriage includes a second bearing arranged to support an inner surface of the second flat portion of the endless belt, and the machine further comprises a second spindle carriage having a second spindle arranged to support a second tire and wheel assembly, the second spindle carriage movably mounted on the frame to move the second spindle toward and away from the second flat portion.
3. The testing machine of claim 1 wherein said at least one axis comprises a steer axis perpendicular to the flat portion.
4. The testing machine of claim 1 wherein said at least one axis comprises a camber axis parallel to the flat portion.
5. The testing machine of claim 4 wherein the roadway assembly is configured to pivotally move relative to the frame about a steer axis that is perpendicular to the flat portion, and the machine further comprises a second actuator to control pivotal movement of the roadway assembly about the steer axis.
6. The testing machine of claim 1 and further comprising a bearing assembly pivotally connecting the carriage to the frame.
7. The testing machine of claim 6 wherein the roadway assembly is configured to pivotally move relative to the frame about a second axis that is perpendicular to the first-mentioned axis, and the machine further comprises a second actuator to control pivotal movement of the roadway assembly about the second axis.
8. The testing machine of claim 7 wherein the bearing comprises a spherical bearing.
9. The testing machine of claim 8 and further comprising a restraint configured to restrain motion of the roadway assembly about a third axis parallel to an axis of rotation of the first roller.
10. The testing machine of claim 7 wherein the bearing comprises a first bearing portion arranged to allow pivotal motion of the roadway assembly about the first axis and a second bearing portion arranged to allow pivotal motion of the roadway assembly about the second axis.
11. The testing machine of claim 1 and further comprising:
a device providing an output indicative of torque, power used, power generated, or forces; and
a controller operably coupled to the device and providing an output indicative of rolling loss of a tire mounted to the spindle.
12. A testing machine comprising:
a frame;
a roadway assembly comprising:
a first roller;
a second roller;
an endless belt supported by and rolling on the first roller and the second roller; and
a carriage supporting the first roller and the second roller in spaced apart relation to cause a first flat portion and a second flat portion in the endless belt, the carriage being pivotally coupled to the frame to move relative to the frame about at least one axis that is perpendicular to an axis that is parallel to an axis of rotation of the first roller, the carriage including a first bearing arranged to support an inner surface of the first flat portion of the endless belt and a second bearing arranged to support an inner surface of the second flat portion of the endless belt;
a first spindle carriage having a first spindle arranged to support a tire and wheel assembly, the first spindle carriage movably mounted on the frame to move the first spindle toward and away from the first flat portion;
a second spindle carriage having a second spindle arranged to support a tire and wheel assembly, the second spindle carriage movably mounted on the frame to move the second spindle toward and away from the second flat portion;
at least one drive operably coupled to the drive roller, the first spindle or the second spindle; and
an actuator to control pivotal movement of the roadway assembly about said at least one axis.
13. The testing machine of claim 12 and further comprising a bearing assembly pivotally connecting the carriage to the frame.
14. The testing machine of claim 13 wherein the roadway assembly is configured to pivotally move relative to the frame about a second axis that is perpendicular to the first-mentioned axis, and the machine further comprises a second actuator to control pivotal movement of the roadway assembly about the second axis.
15. The testing machine of claim 14 wherein the bearing comprises a spherical bearing.
16. The testing machine of claim 15 and further comprising a restraint configured to restrain motion of the roadway assembly about a third axis parallel to an axis of rotation of the first roller.
17. The testing machine of claim 13 wherein the bearing comprises a first bearing portion arranged to allow pivotal motion of the roadway assembly about the first axis and a second bearing portion arranged to allow pivotal motion of the roadway assembly about the second axis.
18. A method of tire testing comprising:
providing a frame; a roadway assembly comprising: an endless belt; and a carriage supporting the endless belt for rotation on the carriage and providing a flat portion in the endless belt, the carriage being pivotally coupled to the frame to move relative to the frame about at least one axis, the carriage including a bearing arranged to support an inner surface of the flat portion of the endless belt; a spindle carriage having a spindle supporting a tire and wheel assembly, the spindle carriage movably mounted on the frame to move the spindle toward and away from the flat portion; a drive operably coupled to the roadway assembly or the spindle; and an actuator to control pivotal movement of the roadway assembly about said at least one axis;
operating the actuator to pivot the roadway assembly relative to the frame and about the axis to obtain a desired position; and
operating the drive to cause rotation of the tire and wheel assembly.
19. The method of claim 18 and comprising calculating a value indicative of rolling loss for the tire.
20. The method of claim 18 wherein the roadway assembly is configured to pivotally move relative to the frame about a second axis that is perpendicular to the first-mentioned axis, and the machine further comprises a second actuator to control pivotal movement of the roadway assembly about the second axis, and the method further comprises the testing machine further comprises operating the second actuator to pivot the roadway assembly relative to the frame and about the second axis to obtain the desired position.
21. The method of claim 20 and comprising calculating a value indicative of rolling loss for the tire.
22. A testing machine comprising:
a frame;
a roadway assembly comprising:
an endless belt; and
a carriage supporting the endless belt for rotation on the carriage and providing a flat portion in the endless belt, the carriage being pivotally coupled to the frame to move relative to the frame about at least one axis, the carriage including a bearing arranged to support an inner surface of the flat portion of the endless belt;
a spindle carriage having a spindle arranged to support a tire and wheel assembly, the spindle carriage movably mounted on the frame to move the spindle toward and away from the flat portion;
a drive operably coupled to the roadway assembly or the spindle; and an actuator to control pivotal movement of the roadway assembly about said at least one axis.
23. The testing machine of claim 22 wherein the roadway assembly is configured to pivotally move relative to the frame about a second axis that is perpendicular to the first-mentioned axis, and the machine further comprises a second actuator to control pivotal movement of the roadway assembly about the second axis.